齐拉西酮与阿立哌唑治疗首发精神分裂症对照研究

A controlled study of ziprasidone and aripiprazole in the treatment of first-episode schizophrenia

目的比较齐拉西酮与阿立哌唑治疗首发精神分裂症的疗效与安全性。方法将60例首发精神分裂症患者随机分为两组各30例，研究组口服齐拉西酮治疗，对照组口服阿立哌唑治疗，观察8w。于治疗前及治疗第1w、2w、4w、8w末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗8w末，研究组与对照组显效率分别为66．7％和63．3％，有效率分别为90．0％和86．7％，两组疗效比较无显著性差异（P〉0．05）。治疗2w末起两组阳性与阴性症状量表评分均较治疗前有显著下降（P〈0．05），并随治疗时间的延续呈持续性下降；8w末研究组精神病理性因子分显著低于对照组（t=2．89，P〈0．01）。研究组不良反应发生率为46．7％，对照组为53．3％，差异无显著性（P〉0．05）。结论齐拉西酮与阿立哌唑治疗首发精神分裂症疗效均显著，且安全性高、依从性好。

Objective To compare the first-episode schizophrenia. Methods efficacy and safety of ziprasidone and aripiprazole in the 60 first-episode schizophrenics were randomly divided treatment of into ziprasidone （n=30） and aripiprazole group （n=30）. The curative effects were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptoms Scale （TESS） before treatment and at the ends of week 1,2,4 and 8 treatment. Results Effectiveness and excellence rates were 90.0% and 66.7% in the ziprasidone and 86.7% and 63.3% in the aripiprazole group respectively, which showed no significant differences（P〉0.05）. Incidence rates of adverse reactions were respectively 46.7% in the ziprasidone and 53.3% in the aripiprazole group, which showed no significant differences（P〉0.05）. Conclusion Ziprasidoue is more effective and safe in the treatment of the first-episode schizophrenia.